Skip to content Skip to footer
Subscribe Now
VIEWPOINTS

Michael Wysocki on Precision Molecular Imaging & PSMA PET Innovation: Blue Earth Diagnostics’ Vision for Personalized Prostate Cancer Care

Shots:  Blue Earth Diagnostics is advancing precision molecular imaging in prostate cancer through its F-18 PET imaging portfolio, with POSLUMA and Axumin designed to improve disease localization, support earlier clinical decision-making, and enhance physician confidence, particularly in patients experiencing biochemical recurrence.  At SNMMI 2026, the company presented new evidence highlighting POSLUMA's strong detection performance at low PSA levels, reduced urinary…
July 13, 2026

Read more

VIEWPOINTS

Turning Genome Data into Clinical Insight: Jehee Suh of Inocras on AI-Driven Genomics 

Shots:  Inocras is advancing the clinical adoption of whole-genome sequencing (WGS) by transforming it from a research tool into a standardized diagnostic workflow, refining its algorithms through thousands of real-world patient cases to deliver actionable genomic insights in routine care.  Through platforms such as CancerVision, RareVision, and MRDVision, the company integrates deep genomic analytics, AI-driven bioinformatics, and clinical services like genetic counseling and…
March 31, 2026

Read more

NEWS

Natera Acquires Foresight Diagnostics for ~$450M to Strengthen Ultrasensitive MRD Testing in Solid Tumors & Lymphoma

Shots: Natera has acquired Foresight Diagnostics, adding its PhasED-Seq phased variant technology with LOD95 of 0.3ppm & detection below 0.1ppm, further enhancing Natera’s capabilities in solid tumor MRD and expanding its IP portfolio of >500 issued/pending patents As per the agreement, Natera completed the acquisition in an all-stock transaction incl. $275M upfront & up to…
December 8, 2025

Read more